WearLinq Acquires AMI Cardiac Monitoring, LLC and Introduces FDA 510(k) Cleared 6-Lead ECG Device, Expanding Clinical Services Nationwide

Wednesday, May 22, 2024

WearLinq, a leading provider of wearable health monitoring and diagnosis solutions, has recently acquired AMI Cardiac Monitoring, LLC, an established independent diagnostic testing facility (IDTF) specializing in ambulatory cardiac monitoring for over 33 years.

This strategic move is set to expand WearLinq’s clinical services nationwide and provide more patients with access to its eWave 6-lead wearable ECG monitor, which recently received FDA 510(k) clearance. The acquisition follows a successful $6.7 million early-stage investment round from SpringTide, Social Impact Capital, Amino Capital, Berkeley Catalyst Fund, Human Longevity, and angel investors from iRhythm and AliveCor.

CEO of WearLinq, expressed optimism about the partnership, stating, “The clinical expertise of AMI combined with WearLinq's advanced technology will create a productive partnership. AMI and WearLinq share the same commitment to providing excellent services for patients and clinical facilities.

This collaboration enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients.”

Atrial fibrillation (AFib) affects one in three individuals during their lifetime, significantly increasing the risk of stroke and often leading to heart failure. However, the current standard of care leaves many patients undiagnosed and untreated, with over 30% receiving false negatives and requiring re-testing within six months. In response, WearLinq has developed an innovative diagnostic solution.

The eWave 6-lead ECG device by WearLinq represents a technological leap in ambulatory cardiac monitoring, offering cardiologists a detailed view of the heart and ensuring exceptional ECG clarity with P-wave visibility. Compatible with patients’ smartphones, it enables long-term monitoring with convenient recharging and attaches magnetically to WearLinq's skin-like adhesive patches.

Company at the forefront of cardiac monitoring innovation. By integrating WearLinq’s advanced 6-lead ECG technology with our clinical expertise, can provide unparalleled cardiac care to patients nationwide, revolutionizing ambulatory cardiac monitoring.

The WearLinq ECG device is designed for patient comfort and clinical accuracy, allowing continuous monitoring of cardiac health while maintaining a normal lifestyle. Integrated with a cloud platform, it ensures near real-time data analysis and actionable insights for healthcare providers.

The company’s commitment to innovation, stating, “This is just the beginning; we have an exciting pipeline of AI products to further empower patients and providers, as well as expand our reach beyond cardiac monitoring. We are dedicated to continuous innovation and broadening our impact across the healthcare spectrum.”

Source: businesswire.com